Kenneth T. Mills left the role of Director at REGENXBIO Inc., effective October 21, 2026. As of November 6, 2026, REGENXBIO Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from August 25, 2026 to October 16, 2026, naming 2 appointments and 1 departure (Form 8-K, October 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like REGENXBIO Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
REGENXBIO Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-08-25 to 2026-10-16. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as REGENXBIO Inc. files it.
Also on the record for REGENXBIO Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 13, 2026 | Stake report, Schedule 13G, by JPMORGAN CHASE & CO. | 5.3% of the class | 5%+ stakes | Source |
| June 4, 2026 | Stake report, Schedule 13G/A, by JPMORGAN CHASE & CO | 4.4% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock Portfolio Management LLC | 4.1% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Redmile Group, LLC | 9.9% of the class | 5%+ stakes | Source |
| July 15, 2025 | Stake report, Schedule 13G, by BlackRock Portfolio Management LLC | 6.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs REGENXBIO Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on REGENXBIO Inc. and the records around it.
REGENXBIO Inc. elsewhere on the record
Companies that share a holder
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- JPMORGAN CHASE & CO also filed stake reports on 116 other companies: LEVI STRAUSS & CO (Nov 2026), Warner Music Group Corp. (Nov 2026), Andersen Group Inc. (Oct 2026)
- BlackRock Portfolio Management LLC also filed stake reports on 118 other companies: AMERISAFE INC (Nov 2026), BlackRock ETF Trust (Nov 2026), iShares J.P. Morgan EM Local Currency Bond ETF (Nov 2026)
Watch REGENXBIO Inc.
Get an email when REGENXBIO Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on REGENXBIO Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on REGENXBIO Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on REGENXBIO Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Out | Director | 2026-10-21 | 8-K, 2026-10-16 | |
| 2026-08-25 | In | Director | 8-K, 2026-08-25 | ||
| 2026-08-25 | In | 8-K, 2026-08-25 |
Who leads REGENXBIO Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Kenneth T. Mills, departure reported, effective 2026-10-21 (filed 2026-10-16). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on REGENXBIO Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at REGENXBIO Inc., with the record behind each one.
Find candidates like Director at REGENXBIO Inc.Every change, in the filing's words
Departing: Kenneth T. Mills, Director, effective 2026-10-21
On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the "Board") of REGENXBIO Inc. (the "Company") effective October 21, 2026.
- Mr. Mills recently became chief executive officer of another company and intends to focus his efforts on his new role.
- Mr. Mills' decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.
- In connection with Mr. Mills' departure, the Board appointed George Migausky as Chairman of the Board ("Chairman").
- In accordance with the Company's Corporate Governance Guidelines, Daniel Tass has stepped down from his position as Lead Independent Director, as the new Chairman is an independent director, but will remain a member of the Board.
Appointed: Gregory Ciongoli, Director
On August 25, 2026, the Board of Directors (the "Board") of REGENXBIO Inc. (the "Company"), elected Gregory Ciongoli as a Class II director of the Company effective immediately.
Appointed: Gregory Ciongoli
The Board also appointed Mr. Ciongoli as a member of the Audit Committee and Nominating and Corporate Governance Committee.
- Mr. Ciongoli's initial term will expire at the Company's 2029 annual meeting of stockholders.
- The Board has determined that Mr. Ciongoli is an independent director in accordance with applicable rules of the U.S. Securities and Exchange Commission (the "SEC") and the Nasdaq Global Select Market.
- Pursuant to the Company's compensation program for non-employee directors, Mr. Ciongoli was granted an initial equity award with an aggregate grant date fair value of $550,000, of which 75% was in the form of a non-statutory stock option and 25% was in the form of restricted stock units ("RSUs"), in each case rounded down to the nearest whole share.
- The exercise price per share for the option was $8.91.
- Mr. Ciongoli will also receive a $45,000 annual retainer for his service on the Board and additional $10,000 and $5,000 annual retainers for his service on the Audit Committee and Nominating and Corporate Governance Committee, respectively.
- Mr. Ciongoli will be eligible to receive annual equity awards upon the conclusion of each annual meeting of stockholders beginning in 2027.
- Mr. Ciongoli will also be entitled to indemnification pursuant to the Company's standard form of director indemnification agreement.
Tools for this story
Each opens in a new tab, filled in for REGENXBIO Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.